EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis

Aishwarya Shukla iD, Matthew Zhang, G Nina Lu iD

Facial Plastic Surgery & Aesthetic Medicine · 01.11.2024 · 26 (6) · 713-719

DOI: 10.1089/fpsam.2024.0026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Facial Plastic Surgery & Aesthetic Medicine, online erschienen am 25.11.2024. Verfasst von Aishwarya Shukla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Synkinesis, Botulinum Toxins, Type A, Eyelids, Neuromuscular Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemodenervation is an important means of treating oral–ocular synkinesis, but upper eyelid treatment is avoided due to risk of blepharoptosis.

Objective

To measure the change in eyelid position among patients with oral–ocular synkinesis who received botulinum toxin to the upper eyelid orbicularis oculi compared with those who received lateral and lower eyelid treatment alone.

Methods

In this retrospective clinical study, patients were categorized as having received lateral and lower eyelid botulinum toxin alone or having received upper eyelid botulinum toxin (to the preseptal and orbital orbicularis oculi) along with lateral and lower eyelid treatment. Pre- and posttreatment margin to reflex distance 1 (MRD1), margin to reflex distance 2 (MRD2), and palpebral height were measured using Emotrics software and compared using t tests and regression analysis.

Results

Twenty-five patients were included. Mean age was 48.7 years and 24% were male. Mean duration of paralysis was 29 months (range 9–360 months). Posttreatment resting MRD1 (3.36) was not significantly different than pretreatment resting MRD1 (3.43) for patients who received upper eyelid botulinum toxin ( p value = 0.60).

Conclusion

Botulinum toxin to the upper eyelid orbicularis oculi injected superficially in small, concentrated aliquots did not result in blepharoptosis and was effective in reducing oral–ocular synkinesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynkinesisBotulinum Toxins, Type AEyelidsNeuromuscular AgentsOculomotor MusclesHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedBlepharoptosis

Stichwörter der Autor:innen

botulinum toxinfacial nervesynkinesis

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Otolaryngology Head and Neck Surgery, University of Washington, Seattle, Washington, USA.
  • Department of Ophthalmology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Aishwarya Shukla, G Nina Lu

Zitieren

APA

Shukla, A., Zhang, M., & Lu, G. N. (2024). Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis. Facial Plastic Surgery & Aesthetic Medicine, 26(6), 713-719. https://doi.org/10.1089/fpsam.2024.0026

Vancouver

Shukla A, Zhang M, Lu GN. Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis. Facial Plastic Surgery & Aesthetic Medicine. 2024;26(6):713-719. doi:10.1089/fpsam.2024.0026

BibTeX
@article{Shukla2024,
  author = {Shukla, Aishwarya and Zhang, Matthew and Lu, G Nina},
  title = {Safety and Efficacy of Upper Eyelid Orbicularis Oculi Botulinum Toxin in Patients with Synkinesis},
  journal = {Facial Plastic Surgery & Aesthetic Medicine},
  year = {2024},
  volume = {26},
  number = {6},
  pages = {713--719},
  doi = {10.1089/fpsam.2024.0026}
}
Kostenlos starten →